publication date: Mar. 4, 2016
20160304 - Mar. 4, 2016
ISSUE 9 – MARCH 4, 2016PDF



NCI Developing Mouse Models To Succeed NCI-60 Cell Lines

The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.

For over 25 years, the NCI-60, a set of about a dozen tissue types—leukemia, non-small cell lung, small cell lung, colon, CNS, melanoma, ovarian, renal, and breast—have been used to perform initial screens on over 100,000 compounds.

 

Conversation with The Cancer Letter

Doroshow: Evidence Suggests PDX Models Come Closer to Simulating Human Cancer

NCI is developing patient-derived xenograft mouse models as a potential substitute for the NCI-60 cell lines, a standard screen which experts say can no longer keep up with advances in cancer research and targeted molecular therapy.

“The goal is to try to understand whether these new models will be more successful in providing a better reflection of the underlying biology in the context of the clinical history and treatment history of patients from whence the tissues came,” said James Doroshow, director of the NCI Division of Cancer Treatment and Diagnosis and deputy director for clinical and translational research.

Slamming the Door

Part VI: The Provost’s Choice

After my conversation with Gilman, I called MD Anderson and asked to talk with somebody about the $18 million grant for a biotech incubator.

First, folks at the press shop told me that they view the controversy arising from the application as CPRIT’s problem.

Let’s see: the wife of president of MD Anderson gets a grant seemingly out of turn, causing a political disaster, and this is not an MD Anderson problem?

National Academy of Medicine Publishes Report on Categorizing Different Ovarian Cancers

Ovarian cancer should not be categorized as a single disease, but as many different cancers involving the ovary, according to a report published by the National Academy of Medicine.

Questions remain on how and where various ovarian cancers arise, said the report that also presents research opportunities for reducing the number of women who are diagnosed with or die from ovarian cancers. Roughly two-thirds of women are diagnosed at an advanced stage when the cancer has already spread beyond the ovary, of which less than 30 percent survive past five years. The report was also sponsored by the Centers for Disease Control and Prevention.

Funding Opportunity

FDA Providing $2 Million for Natural History Studies in Rare Diseases

FDA will provide $2 million in two to five research grants for the study of the natural history of rare diseases. The objective of the grants is to expedite the development of products for these conditions.

The Feb. 29 announcement marks the first time FDA will provide funding through its Orphan Products Grants to collect data on the progression of specific rare diseases in individuals over time.

In Brief

  • Joan Massagué wins Pezcoller-AACR International Cancer Research Award

  • David Weiner named executive vice president at The Wistar Institute

  • Douglas Levine named director of gynecologic oncology at NYU Perlmutter Cancer Center
  • Lauren Streicher joins Northwestern Medical Group as medical director

  • Michael Bukosky appointed chief operating officer of USMD Holdings Inc.

  • International Cancer Genome Consortium authorizes 1,000th user

  • IBM and New York Genome Center to collaborate using Watson technology

  • Vantage Oncology LLC acquired by McKesson Specialty Health

 Drugs and Targets

  • Imbruvica granted approval for first-line CLL patients

  • Health Canada approves Opdivo for metastatic NSCLC

  • FDA grants orphan drug designation to SELLAS’s WT1 cancer vaccine

  • EMA grants orphan drug designation to venetoclax

  • FDA and EMA grant orphan designations to FLAG-003 for glioma

  • Merck KGaA, Pfizer and Verastem enter into avelumab research agreement

  • NanoString Technologies and Merck to collaborate on Keytruda assay

 

Copyright (c) 2019 The Cancer Letter Inc.